{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T07:53:29Z","timestamp":1775894009570,"version":"3.50.1"},"reference-count":12,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2026,1]]},"DOI":"10.1016\/j.eururo.2025.08.020","type":"journal-article","created":{"date-parts":[[2025,9,14]],"date-time":"2025-09-14T04:22:34Z","timestamp":1757823754000},"page":"5-7","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Should We Embark on \u201cEMBARK\u201d? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging"],"prefix":"10.1016","volume":"89","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5339-8038","authenticated-orcid":false,"given":"Giulia","family":"Marvaso","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giulio","family":"Francolini","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"V\u00e9rane","family":"Achard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alfonso","family":"Gomez-Iturriaga","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Finbar","family":"Slevin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Piet","family":"Ost","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2025.08.020_b0005","doi-asserted-by":"crossref","unstructured":"Boorjian SA, Thompson RH, Tollefson MK, et al. Long-term risk of clinical progression after biochemical recurrence following radical prostatectomy: the impact of time from surgery to recurrence. Eur Urol 2011;59:893\u201399. https:\/\/doi.org\/10.1016\/j.eururo.2011.02.026.","DOI":"10.1016\/j.eururo.2011.02.026"},{"key":"10.1016\/j.eururo.2025.08.020_b0010","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.020_b0015","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.eururo.2019.03.016","article-title":"External validation of the European Association of Urology biochemical recurrence risk groups to predict metastasis and mortality after radical prostatectomy in a European cohort","volume":"75","author":"Tilki","year":"2019","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.020_b0020","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.eururo.2024.04.034","article-title":"Risk stratification of patients with recurrence after primary treatment for prostate cancer: a systematic review","volume":"86","author":"Weiner","year":"2024","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2025.08.020_b0025","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.08.020_b0030","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.08.020_b0035","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2025.08.020_b0040","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.52971","article-title":"PSMA-PET\/CT findings in patients with high-risk biochemically recurrent prostate cancer with no metastatic disease by conventional imaging","volume":"8","author":"Holzgreve","year":"2025","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.eururo.2025.08.020_b0045","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/S1470-2045(25)00197-4","article-title":"Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trial","volume":"26","author":"Ost","year":"2025","journal-title":"Lancet Oncol"},{"issue":"5 Suppl","key":"10.1016\/j.eururo.2025.08.020_b0050","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2025.43.5_suppl.15","article-title":"World-wide oligometastatic prostate cancer (omPC) meta-analysis leveraging individual patient data (IPD) from randomized trials (WOLVERINE): an analysis from the X-MET Collaboration","volume":"43","author":"Tang","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2025.08.020_b0055","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/S1470-2045(24)00730-7","article-title":"ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial","volume":"26","author":"Marvaso","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2025.08.020_b0060","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382500497X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S030228382500497X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T15:41:16Z","timestamp":1765986076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S030228382500497X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":12,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2026,1]]}},"alternative-id":["S030228382500497X"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2025.08.020","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2026,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Should We Embark on \u201cEMBARK\u201d? Reassessing the Role of Radiotherapy and Androgen Receptor Pathway Inhibitors in the Era of Next-generation Imaging","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2025.08.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}